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ABSTRACT 
The two active isoforms of Low Molecular Weight Protein Tyrosine Phosphatase (LMW-PTP) have 
inverse cellular effects on cancer.  Isoform A has been found to be anti-oncogenic, while 
overexpression of Isoform B is oncogenic.  Inhibitors of Isoform B could have anti-cancer effects, 
however, it is of utmost importance that these inhibitors exhibit specificity for Isoform B and do not 
affect the function of Isoform A.  Isoform A was recombinantly expressed, purified and 
characterized in order to compare its structure and function to Isoform B.  It is hoped that this 
characterization, along with the synthesis and screening of potential inhibitors for both isoforms, 
will streamline the discovery and optimization of new anti-cancer candidates that specifically target 
LMW-PTP Isoform B. 
 
INTRODUCTION 
   In humans, there are over 100 known 
Protein Tyrosine Phosphatases (PTPs), which 
play many different regulatory roles in 
cellular growth, proliferation, motility, and 
gene expression1. There are four types of 
PTPs, and though they all have a similar 
catalytic phosphate binding loop, they are 
otherwise structurally different2.  The 
smallest of this group, the Low Molecular 
Weight Protein Tyrosine Phosphatases 
(LMW-PTPs), are 18 kD soluble proteins that 
are involved in the regulation and control of 
several signal transducers that modulate cell 
growth and proliferation such as platelet 
derived growth factor receptor (PDGFR), 
epidermal growth factor (EGF), and Ephrin-
A2 receptor (EPHA2). Because of this 
participation in tumorigenic pathways, 
overexpression of LMW-PTP is indicative of 
the onset and proliferation of aggressive 
tumors in breast, colon, bladder, and kidney 
cancers in humans1.  These cancers exhibit 
invasive properties and migrate from their 
origin to other tissues, causing widespread 
damage.  In addition, studies have shown that 
over-expression of LMW-PTP aids in the 
transition of cells from healthy to cancerous3.  
There are two active isoforms of LMW-PTP 
(isoforms A and B) expressed through 
alternative splicing of the ACP1 gene, which, 
as shown in figure 1, differ structurally only 
by a loop flanking the active site1.  Recently it 
has been shown that the two human isoforms 
of LMW-PTP have different effects on tumor 
growth.  Isoform A has been shown to have 
anti-oncogenic properties, whereas Isoform B 
has been shown to be oncogenic5.  New 
specific inhibitors of Isoform B that do not 
affect the activity of Isoform A could 
potentially be used treat and prevent the 
spread of cancer.  In addition, many small 
molecules have been tested for inhibition of 
Isoform B, but their effect on Isoform A is 
unknown. Therefore, further characterization 
of the nuanced differences between the two 
isoforms could streamline the discovery and 
optimization of potential anti-cancer agents 
that specifically target LMW-PTP Isoform B.   
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Figure 1.  Crystal structures of LMW-PTP:    
(a) Isoform A (PDB entry 5PNT); (b) Isoform 
B (PDB entry 1XWW). 
 
   Pyridoxal-5’-Phosphate (PLP), the active 
form of Vitamin B6, effectively inhibits LMW-
PTP Isoform B, but it has numerous cellular 
roles, such as acting as a cofactor of many 
enzymes. This lack of specificity makes it an 
impractical candidate for targeting LMW-PTP.  
In addition to PLP’s lack of selectivity, it is a 
poor substrate of LMW-PTP because the 
phosphorus-oxygen bond is easily hydrolyzed 
by many enzymes present in the cellular 
environment, leading to limited 
bioavailability.  Using molecular docking 
software Maestro (Schroedinger, LLC), 
Pyridoxal 5’-Phosphonate and its analogs, 
which exhibit similar properties to PLP as 
shown in Figure 2, were identified as effective 
LMW-PTP inhibitors4.  Pyridoxal- 5’-
Phosphonate and its analogs are good 
candidates because of the stronger, non-
hydrolysable carbon-phosphorus bond4.  If 
these phosphonate inhibitors strongly inhibit 
Isoform B while leaving Isoform A unaffected, 
they could be potential anti-cancer drug 
candidates.  
 
 
 
Figure 2.  Comparison of PLP and potential 
inhibitor, Pyridoxal 5’-Phosphonate. 
 
   The specificity of inhibitors needs to be 
evaluated by comparative assays of the two 
isoforms.  Isoform B was previously 
expressed and many small molecules have 
been assessed for inhibitory properties.  
However, no assays have been done with 
Isoform A, so the specificity of the tested 
inhibitors is unknown.  In order to correct 
this, Isoform A was expressed, purified, and 
refolded to yield active enzyme.  This makes 
the Isoform A comparison assays possible, 
which will lead to a better understanding of 
the small molecule properties that provide 
the best specificity for Isoform B.  
 
RESULTS AND DISCUSSION 
   Expression and Characterization of 
Isoform A.  A pEx expression vector with an 
amino-terminal polyhistidine tag and 
synthetic ACP1 mRNA variant 3 gene was 
obtained from Blue Heron Biotech, LLC, and 
expressed in BL21 competent E. coli.  
Induction of expression was successful and 
the protein was purified using a Ni-NTA 
affinity column.  The resulting protein was  
a 
b 
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Figure 3. (a) SDS-PAGE analysis of LMW-PTP 
Isoform A expressed with N-terminal 
polyhistidine tag.  Lane 1 contains protein 
that did not bind to the column and came 
through with wash buffer (20 mM Tris, 0.3 M 
NaCl, 25 mM imidazole), lane 2 contains 
Precision Plus Protein Dual Color Standard 
(Bio-Rad), and lane 3 contains protein eluted 
from the column with elution buffer (20 mM 
Tris, 0.3 M NaCl, 0.25 M imidazole); (b) 
Enzyme activity assay results for N-
terminally tagged Isoform A (Concentration 
of 1 = 0.11 mg/mL). 
 
analyzed by SDS-PAGE, and the molecular 
weight was determined to be approximately 
19 kD (Figure 3a). Enzymatic activity was 
then assessed by an in vitro assay that was 
developed to measure inhibitory properties 
of small molecules on Isoform B.  The 
 
 
 
 
 
Figure 4. (a) SDS-PAGE analysis of LMW-PTP 
Isoform A expressed with C-terminal 
polyhistidine tag Lane 1 contains protein that 
did not bind to the column and came through 
with wash buffer (20 mM Tris, 0.3 M NaCl, 25 
mM imidazole), Precision Plus Protein Dual 
Color Standard (Bio-Rad), and lane 3 contains 
protein eluted from the column with elution 
buffer (20 mM Tris, 0.3 M NaCl, 0.25 M 
imidazole); (b) Enzyme activity assay results 
for C-terminally tagged Isoform A 
(Concentration of 1 is approximately 0.01 
mg/mL ). 
 
substrate used in this assay is p-nitrophenyl  
phosphate, which is enzymatically hydrolyzed 
to form the product p-nitrophenol, which, 
when placed in a basic environment, can be 
detected by absorbance spectroscopy at 405 
1. Wash 
2. MW 
Ladder 
3. Eluted 
Protein 
2. MW 
Ladder 
3. Eluted 
Protein 
a 
b 
a 
b 
1. Wash 
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nm.  This substrate is reportedly compatible 
with Isoform A5.  However, when the 
recombinant Isoform A was assayed, no 
activity was observed (Figure 3b). 
   Since the affinity tag was potentially 
interfering with protein folding during 
translation, a new pEx vector with a carboxy-
terminal polyhistidine tag was obtained and 
expressed in the same conditions as the 
amino-terminal vector.  However, as shown in 
Figure 4a, the protein was not as robustly 
expressed.  It was determined through SDS-
PAGE analysis that the purified protein had a 
molecular weight of approximately 30, which 
is far from the expected molecular weight of 
18 kD. The C-terminally tagged protein was 
then assayed, and once again showed no 
activity, as shown in Figure 4b. 
   As moving the affinity tag to the C-terminal 
end of the protein did not yield active protein, 
refolding of the protein was attempted.  The 
N- terminally tagged Isoform A was used  
 
since its expression was more reliable and the 
molecular weight was much nearer to the 
expected value.  The protein was purified in 
denaturing conditions (6M guanidine) and 
subjected to nine different conditions with 
differing levels of the denaturants guanidine 
and L-arginine as well as differing redox 
environments.  The results of this experiment 
are shown in Table 1.  Refolding of Isoform A 
measured by recovery of activity in the assay 
described above was most effectively 
achieved by a reduced to oxidized glutathione 
ratio of 10:1 and 0.48 M guanidine.  Control 
experiments were run on Isoform B, which 
was previously expressed as a glutathione S-
transferase (GST) fusion protein, to verify 
whether refolding conditions interfered with 
the activity assay.  The buffer conditions did 
not appear to interfere, as Isoform B showed 
trends very similar to Isoform A in refolding 
behavior (Table 1). 
 
Table 1.  The effect of denaturant and redox conditions on protein refolding measured by recovery 
of activity (significant recovery denoted by +, modest recovery by 0, and no recovery by -).  All 
buffer conditions also contained 1 mM EDTA, 50 mM Tris, 20 mM NaCl, and 0.8 mM KCl. 
Buffer 
Condition 
Guanidine 
(M) 
L-Arginine 
(M) 
Reduced  
Glutathione 
(mM) 
Oxidized  
Glutathione 
(mM) 
Isoform A 
Refolding 
Isoform B 
Refolding 
1 0.48 0 20 2 + + 
2 0.48 0.4 20 4 + + 
3 0.48 0.8 10 10 0 0 
4 0.98 0 20 4 0 0 
5 0.98 0.4 10 10 0 0 
6 0.98 0.8 20 2 0 0 
7 1.48 0 10 10 - - 
8 1.48 0.4 20 2 - - 
9 1.48 0.8 20 4 - - 
 
 
Synthesis of inhibitors. Previous in silico 
docking experiments using Maestro 
(Schroedinger, LLC) identified pyridoxal 5’ 
phosphonate and its analogs as good inhibitor 
candidates.   They are being synthesized 
through the synthetic scheme shown in figure  
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Figure 5. Synthetic scheme for target phosphonate analogs. 
5.  The addition of the protection group to 
yield intermediate A was unsuccessful unless 
everything was completely anhydrous.  After 
distillation of the acetone and 2, 2- dimethoxy 
Sinner 6 
 
propane, and vacuum drying of the 
pyridoxine and p-toluenesulfonic acid, 
intermediate A was formed with good yield 
and verified through 1H NMR.  The oxidation 
of A to B catalyzed by pyridinium 
chlorochromate was fairly successful as 
indicated by the appearance of an aldehyde 
peak (10.03 ppm) on a scale less than or 
equal to 1 gram, but was difficult to scale up.   
Increased purity of intermediate A led to 
increased yield of intermediate B.  Tetraethyl-
methylene diphosphonate was then used in a 
Horner-Wittig reaction to form C, which was 
effectively purified using a silica gel column 
with a water/methanol/ethyl acetate 
v/v=1/10/89 mobile phase.  Both E and Z 
isomers were formed, but since it is desirable 
for both the alkane and alkene analogs to be 
synthesized and tested for inhibitory activity 
in both isoforms of LMW-PTP, the fractions 
that were not isomerically pure were saved 
for hydrogenation.  The removal of the 
isopropylidene protecting group was 
achieved through reflux with hydrochloric 
acid in methanol, though in later trials 
removal of intermediate D was required 
several times to shift the equilibrium and get 
an acceptable yield.    Deprotection of the 
phosphonate to form compound 1 was 
difficult due to very limited solubility of 
intermediate D in dichloromethane.   Several 
other solvents were tested, and solubility was 
very low in all of the solvents compatible with 
the reactions.  Since it was suspected that the 
pyridyl nitrogen had formed the 
hydrochloride salt, conversion to the basic 
form was attempted with sodium hydride, but 
was not successful.    The oxidation of the 
second alcohol to form intermediate E was 
attempted using the same procedure as the 
oxidation to form intermediate B.  Due to the 
increased polarity of the compound, it was 
not possible to extract it from the aqueous 
layer.  The water was therefore removed 
from the sample on a speedvac in an attempt 
to isolate the product.  However, formation of 
the aldehyde was not verified either by 1H 
NMR or testing with 2, 4-
dinitrophenylhydrazine.  Once the conditions 
for the synthesis and purification of 
compounds 1 and 2 are optimized, the 
hydrogenation of C to F will be performed, 
and the same conditions will be used to 
obtain compounds 3 and 4. 
CONCLUSION 
The expression of LMW-PTP Isoform A and 
the subsequent refolding procedure allows 
for production of the active form of the 
enzyme.  This procedure needs to be scaled 
up before it is a viable method of procuring 
active Isoform A.  Once a larger scale method 
is optimized, further characterization of this 
protein, such as the acquisition of circular 
dichroism (CD) data, will need to be done.  
This characterization, as well as a detailed 
comparison to Isoform B, will further 
streamline the process of finding good, 
selective inhibitors for Isoform B.  Once active 
Isoform A is produced on a larger scale, all 
the small molecules previously tested on 
Isoform B can be tested for inhibition of 
Isoform A.  In addition, once the synthesis of 
the phosphonate analogs of PLP is complete, 
they can be tested for inhibition of both 
isoforms.  The results of these assays will help 
to identify structural motifs that impart 
inhibitor specificity for one isoform over the 
other, which will simplify the process of 
developing effective anti-cancer agents that 
target LMW-PTP Isoform B. 
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EXPERIMENTAL 
   Introduction of plasmid into cells. The 
pEx expression vector (0.1 µL, 50.1 ng/µL) 
obtained from Blue Heron Biotechnology, 
LLC, was added to BL21 competent E. coli 
cells (New England BioLabs) and incubated 
on ice for 30 minutes.  The cells were then 
heat shocked at 42°C for 10 seconds, followed 
by incubation on ice for 5 minutes.  
Subsequently, 900 µL of cold SOC medium 
was added and incubated at 37°C with 225 
rpm shaking for 1 hour.  Cells (100 µL, 1X and 
0.1X) were plated on LB/ampicillin agar 
plates and incubated at 37°C for 18 hours. 
   Protein expression.  One colony from the 
plates from the above step was inoculated 
into each of 4 sterile aliquots of LB media (5 
mL) to which ampicillin (10 µL, 50 mg/mL) 
had been freshly added.  The cells were then 
grown in liquid culture at 37°C with 225 rpm 
shaking for 18 hours.  Cells were then 
archived in 40% glycerol solution and stored 
at -80°C.  The glycerol stock was then grown 
in liquid culture as previously described.  The 
liquid culture (2 mL) was added to each of 5 
aliquots of sterile LB (200 mL) to which 
ampicillin (400 µL, 50 mg/mL) was freshly 
added.  The aliquots were then incubated at 
37°C with 225 rpm shaking for 4 hours.  
Absorbance at 600 nm was used to monitor 
cell growth, and isopropylthio-D-galactoside 
(IPTG; 200 µL, 24 mg/mL) was added to each 
aliquot when A600 reached 0.4 to induce 
protein expression.  The aliquots were 
incubated at 37°C with 225 rpm shaking for 3 
hours, followed by centrifugation at 5000X g 
for 10 minutes.       The pellet was then 
isolated and resuspended in B-PER Bacterial 
protein extraction reagent (Thermo 
Scientific) at 4 mL per gram of cell pellet.  The 
suspension was incubated at room 
temperature for 15 minutes before being 
centrifuged at 15000X g for 5 minutes.  The 
soluble protein was then isolated and stored 
at -80°C.   
  Purification of protein.  The soluble 
protein extract described above was purified 
using Ni-NTA resin (Thermo Scientific).  
Sample was loaded in 1:1 equilibration buffer 
(20 mM TRIS, 0.3 M NaCl, 10 mM Imidazole, 
pH 10.0).  The column was washed with wash 
buffer (20 mM TRIS, 0.3 M NaCl, 25 mM 
Imidazole, pH 10.0) until A280 reached 
baseline.  Protein was eluted with elution 
buffer (20 mM TRIS, 0.3 M NaCl, 0.25 M 
Imidazole, pH 10.25) and analyzed for purity 
and molecular weight through SDS-PAGE. 
   Purification of protein in denaturing      
conditions. Protein was purified as described 
above except with 6 M GuHCl present in each 
buffer. 
   Enzyme activity assay. E-pure water (180 
µL), 1.0 M sodium acetate/acetic acid buffer 
solution (25 µL), and 50 mM p-nitrophenyl 
phosphate (25 µL) were added to 0.5 mL 
microcentrifuge tubes and mixed well.  The 
protein being assayed (20 µL) was then 
added at timed intervals and incubated for 30 
minutes.  The reaction was quenched by 
transferring 20 µL of the reaction mixture to a 
well of a 96 well plate containing 100 µL of 
0.5 M KOH.  Absorbance was then measured 
at 405 nm. 
   Refolding assay. Protein purified in 
denaturing conditions was added in 20 µL 
increments to each of 9 tubes containing 10 
mM EDTA and differing amounts of 
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guanidine, L-arginine, reduced glutathione, 
and oxidized glutathione followed by 
incubation at 4°C for 24 hours.  Buffers were 
obtained from Pierce Biotechnology, Inc.  
Activity was assessed in the same manner 
described above except the reaction was run 
for 18 hours instead of 30 minutes due lower 
protein concentration. 
   Synthesis of 3, 4’-o-isopropylidene 
pyridoxine (A).  Distilled acetone (60 mL), 
distilled 2, 2-dimethoxy propane (40 mL), and 
vacuum dried pyridoxine HCl (4 g, 19.52 
mmol) was added to a 250 mL round bottom 
flask containing p-toluenesulfonic acid (13.24 
g, 78.08 mmol) that had been dried at 115°C 
on a kugelrohr vacuum distillation apparatus 
for 6 hours.   The yellow-orange suspension 
that formed was stirred for 24 hours at room 
temperature in a dry environment 
maintained by a calcium carbonate filled 
drying tube.  The reaction mixture, now dark 
brown, was neutralized by solid sodium 
bicarbonate, filtered, and concentrated.  The 
remaining dark brown solid was dissolved in 
brine (8 mL) and extracted with 
dichloromethane.  The organic fractions were 
washed with water and dried over sodium 
sulfate, and concentrated.  The cream colored 
solid product (2.748 g, 68.7%) was 
recrystallized by dissolution in ethanol 
followed by precipitation by the addition of 
cold diethyl ether.  1H NMR (CDCl3, 400 MHz): 
δ (ppm) 7.84 (s, 1H), 4.93 (s, 2H), 4.55 (s, 2H), 
2.37(s, 3H), 1.54 (s, 6H). 
   Synthesis of 2,2,8-trimethyl-4H-
[1,3]dioxino[4,5-c]pyridine-5-
carbaldehyde (B).    Compound A (1.0 g, 4.8 
mmol), pyridinium chlorochromate ( 1.03 g, 
4.8 mmol), and pyridine (14 mL) were added 
to a 25 mL round bottom flask and refluxed at 
115°C for 90 minutes.  After the reaction 
mixture had cooled to room temperature, 
diethyl ether (35 mL) was added.  The black 
precipitate that formed was then filtered off, 
and the filtrate was then washed with water.  
The organic fractions were dried with sodium 
sulfate and concentrated to give a brown oil 
(0.504 g, 50.4%).  1H NMR (CDCl3, 400 MHz): 
δ (ppm) 10.03 (s, 1H), 8.46 (s, 1H), 5.17 (s, 
2H), 2.50 (s, 3H), 1.56 (s, 6H). 
   Synthesis of diethyl (E)-(2-(2,2,8-
trimethyl-4H-[1,3]dioxino[4,5-c]pyridin-
5-yl)vinyl)phosphonate (C).  Lithium 
diisopropylamide (1 M in THF, 1.5 mL) in a 25 
mL round bottom was cooled to -78°C in a dry 
ice/acetone bath in a nitrogen environment.  
Tetraethyl-methylenediphosphonate (0.66 
mL, 2.65 mmol) was mixed with 
tetrahydrofuran (3 mL) and added to the 
flask and the mixture was stirred for 1 hour.  
Compound B (0.5 g, 2.414 mmol) was 
dissolved in 6 mL tetrahydrofuran and added 
to the flask, followed by stirring for 45 
minutes.  The reaction mixture was then 
allowed to slowly warm to room 
temperature, and it was then refluxed for 2 
hours at 100°C.  After cooling to room 
temperature, the reaction was quenched with 
saturated aqueous ammonium chloride 
followed by extraction with diethyl ether.  
The organic fractions were then dried with 
sodium sulfate, filtered and concentrated to 
give yellow oil.  Purification of crude product 
was done by silica gel column 
chromatography (1 x 20 cm, 63-200 mesh 
silica gel, eluent: water/methanol/ethyl 
acetate, v/v=1/10/89) to give pure product C 
(0.385 g, 77%). 1H NMR (CDCl3, 400 MHz): δ 
(ppm) 8.23 (s, 1H), 7.30 (dd, 1H), 6.21 (t, 1H), 
4.90 (s, 2H), 4.14 (quint, 4H), 2.43 (s, 3H), 
1.55 (s, 6H), 1.36 (t, 6H). 
   Synthesis of diethyl (E)-(2-(5-hydroxy-4-
(hydroxymethyl)-6-methylpyridin-3-
yl)vinyl)phosphonate (D). Compound C 
(.327 g, 9.59 mmol) was dissolved in 
methanol (0.5 mL) and added to a 25 mL 
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round bottom flask.  Hydrochloric acid (4 mL, 
1.25 M in methanol) was added to the flask 
followed by reflux for 2 hours at 60°C.  The 
reaction mixture was neutralized with solid 
sodium bicarbonate, filtered, and 
concentrated.  The resulting sticky brown 
substance was washed with diethyl ether to 
yield product D (.267 g, 81.6%).   1H NMR 
(D2O, 400 MHz): δ (ppm) 7.79 (s, 1H), 7.62 
(dd, 1H), 6.32 (t, 1H) 4.74 (s, 2H), 4.06 (quint, 
4H), 2.34 (s, 3H), 1.22 (t, 6H).   
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SUPPLEMENTARY INFORMATION 
 
 
Supplementary Figure 1.  Activity analysis of both N-terminally and C-terminally tagged Isoform A 
and control Isoform B. 
 
 
 
Supplementary Figure 2. Schematics of expression vectors with N-terminal and C-terminal 
polyhistidine tags. 
 
 
 
 
 
R² = 0.9991
-0.5
0.5
1.5
2.5
0 0.5 1
A
4
0
5
Relative Concentration
Isoform B
